- Clinical-stage biopharmaceutical drug development company Belite Bio (NASDAQ:BLTE) appointed Hendrik P. N. Scholl, MD, MA, as the chief medical officer of the company, effective immediately.
- Dr. Scholl is the foremost globally recognized authority on Stargardt disease and age-related macular degeneration, bringing decades of expertise in treating retinal diseases, including the two key indications targeted by Belite Bio’s lead drug candidate, Tinlarebant.
- Recently, he served as Professor of Ophthalmology and Endowed Chair at the Wilmer Eye Institute of Johns Hopkins University Medical School.
